Dashboard
Manage Tickers

NAMS NewAmsterdam Pharma Co N.V.

Nasdaq newamsterdampharma.com


$ 35.75 $ -0.56 (-1.56 %)    

Friday, 24-Oct-2025 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 35.72
$ 36.60
$ 34.48 x 50
$ 37.07 x 9
$ 35.12 - $ 37.21
$ 14.06 - $ 41.47
746,400
na
4.02B
$ 1.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-26-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

deep-dive-into-newamsterdam-pharma-co-stock-analyst-perspectives-4-ratings
Deep Dive Into NewAmsterdam Pharma Co Stoc...
10/20/2025 12:03:11

hc-wainwright--co-assumes-newamsterdam-pharma-co-at-buy-announces-price-target-of-52
HC Wainwright & Co. Assumes NewAmsterdam P...
10/20/2025 10:46:53

HC Wainwright & Co. analyst Joseph Pantginis assumes NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announce...

citigroup-maintains-buy-on-newamsterdam-pharma-co-raises-price-target-to-50
Citigroup Maintains Buy on NewAmsterdam Ph...
10/17/2025 15:27:30

Citigroup analyst Geoff Meacham maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $...

expert-outlook-newamsterdam-pharma-co-through-the-eyes-of-6-analysts
Expert Outlook: NewAmsterdam Pharma Co Thr...
08/25/2025 12:01:23

wells-fargo-initiates-coverage-on-newamsterdam-pharma-co-with-overweight-rating-announces-price-target-of-45
Wells Fargo Initiates Coverage On NewAmste...
08/25/2025 11:27:09

Wells Fargo analyst Yanan Zhu initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Overweight rating and announ...

newamsterdam-pharma-and-piramal-pharma-solutions-invest-multi-million-dollars-in-dedicated-oral-solid-dosage-suite-at-sellersville-pennsylvania-facility
NewAmsterdam Pharma And Piramal Pharma Sol...
08/21/2025 07:24:23

The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of o...

what-5-analyst-ratings-have-to-say-about-newamsterdam-pharma-co
What 5 Analyst Ratings Have To Say About N...
08/07/2025 22:03:05

rbc-capital-maintains-outperform-on-newamsterdam-pharma-co-raises-price-target-to-39
RBC Capital Maintains Outperform on NewAms...
08/07/2025 15:07:51

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price ta...

newamsterdam-pharma-q2-eps-015-beats-046-estimate-sales-19145m-beat-2235m-estimate
NewAmsterdam Pharma Q2 EPS $(0.15) Beats $...
08/06/2025 21:51:42

NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $...

newamsterdam-pharma-q2-eps-015-beats-046-estimate-sales-19145m-beat-2235m-estimate
NewAmsterdam Pharma Q2 EPS $(0.15) Beats $...
08/06/2025 11:19:53

newamsterdams-obicetrapib-reduces-alzheimers-biomarker-p-tau217-in-high-risk-apoe4-carriers-supporting-cetp-inhibition-as-potential-preventive-approach
NewAmsterdam's Obicetrapib Reduces Alzheim...
07/30/2025 12:27:20

-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzhei...

biotech-says-its-cholesterol-drug-shows-signs-of-preventing-alzheimers-newamsterdam-pharma-hopes-medicine-born-out-of-big-failures-may-have-an-unexpected-benefit---stat-news
'Biotech Says Its Cholesterol Drug Shows S...
07/30/2025 12:25:16

https://www.statnews.com/2025/07/30/new-amsterdam-pharma-cholesterol-drug-alzheimers/

goldman-sachs-initiates-coverage-on-newamsterdam-pharma-co-with-neutral-rating-announces-price-target-of-27
Goldman Sachs Initiates Coverage On NewAms...
07/17/2025 11:21:24

Goldman Sachs analyst Asad Haider initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral rating and anno...

citigroup-initiates-coverage-on-newamsterdam-pharma-co-with-buy-rating-announces-price-target-of-42
Citigroup Initiates Coverage On NewAmsterd...
06/17/2025 11:41:41

Citigroup analyst Geoff Meacham initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces P...

what-analysts-are-saying-about-newamsterdam-pharma-co-stock
What Analysts Are Saying About NewAmsterda...
06/12/2025 13:01:09

needham-reiterates-buy-on-newamsterdam-pharma-co-maintains-40-price-target
Needham Reiterates Buy on NewAmsterdam Pha...
06/12/2025 10:29:49

Needham analyst Serge Belanger reiterates NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and maintains $40 price target.

stifel-initiates-coverage-on-newamsterdam-pharma-co-with-buy-rating-announces-price-target-of-44
Stifel Initiates Coverage On NewAmsterdam ...
06/10/2025 14:25:38

Stifel analyst James Condulis initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces Pri...

analyst-says-newamsterdam-stock-has-over-100-upside-citing-90-success-probability-for-obicetrapib
Analyst Says NewAmsterdam Stock Has Over 1...
06/09/2025 16:23:57

NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of ...

newamsterdam-pharma-announced-topline-data-from-prespecified-alzheimers-disease-biomarker-analyses-in-the-phase-3-broadway-trial-of-obicetrapib
Newamsterdam Pharma Announced Topline Data...
06/09/2025 11:04:30

Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions ...

newamsterdam-pharma-scheduled-to-participate-in-june-investor-conferences
NewAmsterdam Pharma Scheduled to Participa...
05/29/2025 20:19:58

William Blair 45th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 3, 2025. Michael Davidson, M.D., Chief Execut...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION